Redhill Biopharma Ltd. (RDHL) News

Redhill Biopharma Ltd. (RDHL): $0.96

0.05 (+5.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RDHL News Items

RDHL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RDHL News Highlights

  • For RDHL, its 30 day story count is now at 4.
  • Over the past 10 days, the trend for RDHL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about RDHL are NOVA.

Latest RDHL News From Around the Web

Below are the latest news stories about RedHill Biopharma Ltd that investors may wish to consider to help them evaluate RDHL as an investment opportunity.

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for the fourth quarter of 2021, including certain estimated unaudited preliminary financial data.

Yahoo | February 17, 2022

RedHill Biopharma says oral COVID-19 therapy lowered mortality in hospitalized patients

Announcing data from a Phase 2/3 trial for its COVID-19 therapy opaganib, RedHill Biopharma (RDHL -2.4%) said Monday that the oral treatment “significantly reduced” death among hospitalized patients who had previously received standard-of-care (SOC). According to the prespecified mortality analysis, among those who were receiving SOC of remdesivir and corticosteroids,...

Seeking Alpha | February 7, 2022

CLARET ASSET MANAGEMENT Corp Buys Bristol-Myers Squibb Co, Shopify Inc, Hertz Global Holdings ...

Investment company CLARET ASSET MANAGEMENT Corp (Current Portfolio) buys Bristol-Myers Squibb Co, Shopify Inc, Hertz Global Holdings Inc, Newmont Corp, Sangoma Technologies Corp, sells Berkshire Hathaway Inc, Apple Inc, Bank of Montreal, Boeing Co, Bank of Nova Scotia during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CLARET ASSET MANAGEMENT Corp.

Yahoo | February 7, 2022

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two recently completed prespecified analyses from the oral opaganib (ABC294640)[1] Phase 2/3 study in hospitalized severe COVID-19. The first analysis showed that opaganib significantly reduced mortality when given to patients who received remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients. A second analysis furth

Yahoo | February 7, 2022

Henry James International Management Inc. ...

Investment company Henry James International Management Inc. (Current Portfolio) buys Alibaba Group Holding, iShares MSCI Emerging Markets ETF, Materialise NV, EPAM Systems Inc, Endava PLC, sells Core Laboratories NV, Betterware de Mexico SAB de CV, Gazprom PJSC, Piedmont Lithium Inc, Cellectis SA during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Henry James International Management Inc..

Yahoo | January 18, 2022

RedHill says oral COVID-19 therapy improved viral clearance in severely ill patients

RedHill Biopharma (RDHL) announced that its oral COVID-19 therapy opaganib “significantly” improved viral clearance in a Phase 2/3 trial involving severely ill hospitalized patients…

Seeking Alpha | January 13, 2022

RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance

RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The data demonstrated that opaganib improved the median time to viral RNA clearance by at least four days. Treatment with opaganib resulted in viral RNA clearance in a median of 10 days, while the median for clearance in the placebo arm was not reached by the end of 14-days of treatment for placebo. Related: Why Did RedHill Biopharma Shares Ju

Yahoo | January 13, 2022

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new data from a prespecified analysis of all oral opaganib's[1] Phase 2/3 study patients with positive PCR at screening, demonstrating that opaganib improved the median time to viral RNA clearance by at least 4 days. Treatment with opaganib resulted in viral RNA clearance in a median of 10 days while the median for clearance in the placebo arm was not reached by the end of 1

Yahoo | January 13, 2022

RedHill Biopharma inks licensing deal for Talicia in UAE

RedHill Biopharma <> has entered into an exclusive license agreement with Gaelan Medical, a wholly owned subsidiary of the Ghassan Aboud Group, for Talicia (omeprazole

Seeking Alpha | January 6, 2022

RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Gaelan Medical Trade LLC ("Gaelan Medical"), a wholly owned subsidiary of the Ghassan Aboud Group (GAG), for Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1], an H. pylori therapy, in the United Arab Emirates (UAE).

Yahoo | January 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4229 seconds.